Abstract
Poliomyelitis has appeared in epidemic form, become endemic on a global scale and has been reduced to near elimination, all within the span of documented medical history. Environmental surveillance of poliovirus (PV) means monitoring of PV transmission in human populations by examining environmental specimens supposedly contaminated by human faeces. The rationale for surveillance is based on the fact that PV-infected individuals, whether presenting with disease symptoms or not, shed large amounts of PV in the faeces for several weeks. As the morbidity: infection ratio of PV infection is very low, this fact contributes to the sensitivity of PV surveillance, which under optimal conditions can be better than that of the standard acute flaccid paralysis (AFP) surveillance. The World Health Organization (WHO) has included environmental surveillance of PV in the new Strategic Plan of the Global Polio Eradication Initiative for years 2010–2012 to be increasingly used in PV surveillance, supplementing AFP surveillance.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Andrus JK, Thapa AB, Withana N et al (2001) A new paradigm for international disease control: lessons learned from polio eradication in Southeast Asia. Am J Public Health 91:146–150
Barrett S (2009) Polio eradication: strengthening the weakest links. Health Aff (Millwood) 28:1079–1090
Blomqvist S, Savolainen C, Laine P, Hirttio P, Lamminsalo E, Pentilla E et al (2004) Characterisation of a highly evolved vaccine derived poliovirus type 3 isolated from sewage in Estonia. J Virol 78:4876–4883
Blume S, Geesink I (2000) A brief history of polio vaccines. Science 288:1593–1594
Blume SS (2005) Lock in, the state and vaccine development: lessons from the history of the polio vaccines. Res Policy 34:159–173
Buttinelli G, Donati V, Fiore S et al (2003) Nucleotide variation in sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. J Gen Virol 82:79–91
Centers for Disease Control and Prevention (2001) Circulation of a type 2 vaccine-derived poliovirus-Egypt, 1982–1993. Morb Mortal Wkly Rep 50(41–42):51
Centers for Disease control and Prevention (2002) Progress towards global eradication of poliomyelitis, 2001. Morb Mortal Wkly Rep 51:253–256
De Jesus NH (2007) Epidemics to eradication: the modern history of poliomyelitis. Virol J 4:70
Divizia M, Palombi L, Buonomo E, Donia D, Ruscio V, Equestre M et al (1999) Genomic characterization of human and environmental polioviruses isolated in Albania. Appl Environ Microbiol 65:3534–3539
Dove A (2001) Paralytic poliomyelitis returns to the Western Hemisphere. PICO News, Caribbean Outbreak
Estı′variz CF, Molna′r Z, Venczel L et al (2011) Paralytic poliomyelitis associated with sabin monovalent and bivalent oral polio vaccines in Hungary. Am J Epidemiol 174:316–325
Friedrich F (2000) Genomic modifications in oral poliovirus vaccine strains after multiplication in humans and implications for the eradication of poliovirus. Acta Virol 44:109–117
Georgopoulou A, Markoulatos P, Spyrou N, Vamvakopoulos NC (2000) Improved genotyping vaccine and wild-type poliovirus strains by restriction fragment length polymorphism analysis: clinical diagnostic implications. J Clin Microbiol 38:4337–4342
Ghendon Y, Robertson SE (1994) Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Organ 72:973–983
Grassly NC, Jafari H, Bahl S et al (2009) Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J Infect Dis 200:794–801
Heymann DL, Sutter RW, Aylward RB (2006a) A vision of a world without polio: the OPV cessation strategy. Biologicals 34(2):75–79
Heymann DL, Sutter RW, Aylward RB (2006b) Polio eradication: interrupting transmission, towards a polio-free world. Future Virol 1:181–188
Horie H, Yoshida H, Matsuura K, Miyazawa M, Wakabayashi K, Nomoto A, Hashizume S (2002) Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan. J Med Virol 68:445–451
Hovi T, Lindholm N, Savolainen C, Stenvik M, Burns C (2004) Evolution of wild type 1 poliovirus in two healthy siblings excreting the virus over a period of 6 months. J Gen Virol 85:369–377
John T, Jain H, Ravishankar K et al (2011) Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials. Vaccine 5:5793–5801
Kaura G, Abraham T (2012) Polio eradication: a complex end game. BMJ 344:e2398
Kew OM, Sutter RW, Nottay BK et al (1998) Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol 36:3893–2899
Kew OM, Wright PF, Agol VI (2004) Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ 82:16–23
Martin J, Ferguson GL, Wood DJ, Minor PD (2000) The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland. Virology 278:42–49
Martin J (2011) Detection and characterization of polioviruses. Methods Mol Biol (Cliffton) 665:233
Modlin JF (2010) The bumpy road to polio eradication. N Engl J Med 362:2346–2349
Mukherji WCS, Jindal LCAK, Singh BZ et al (2005) Polio eradication in India: myth or reality. Med J Arm Forces Ind 61:364–366
Mulders MN, Reimerink JHJ, Stenvik M, Alaeddinoglu I, van der Avoort HGAM et al (1999) A sabin vaccine-derived field isolate of poliovirus type 1 displaying aberrant phenotypic and genetic features, including a deletion in antigenic site. J Gen Virol 80:907–916
Nathanson N (2008) The pathogenesis of poliomyelitis: what we don’t know. Adv Virus Res 71:1–50
Nwachuku N, Gerba CP (2006) Health risks of enteric viral infections in children. Rev Environ Contam Toxicol 186:1–56
Kew O (2012) Reaching the last one per cent: progress and challenges in global polio eradication. Curr Opin Virol 2:188–198
Paul Y (2007) Role of genetic factors in polio eradication: new challenge for policy makers. Vaccine 25:8365–8371
Pelczar MJ Jr, Chan ECS, Krieg NR (1993) Microbiology: concepts and applications. McGraw-Hill Inc., New York 698
Racaniello VR (2006) One hundred years of poliovirus pathogenesis. Virology 344:9–16
Rousset D, Rakoto-Andrianarivelo M, Razafindratsimandresy R et al (2003) Recombinant vaccine-derived poliovirus in Madagascar. Emerg Infect Dis 9:885–887
Sabin AB (1956) Pathogenesis of poliomyelitis; reappraisal in the light of new data. Science 123:1151–1157
Sathyamala C, Mittal O, Dasgupta R et al (2005) Polio eradication initiative in India: deconstructing the GPEI. Int J Health Serv 2:361–383
Shulman LM, Manor J, Handsher R, Delpeyroux F, MacDonough MJ, Halmut T et al (2000) Molecular and antigenic characterisation of a highly evolved derivative of the type 2 oral polio vaccine strain isolated from sewage in Israel. J Clin Microbiol 38:3729–3734
Sutter RW, Prevots DR (1994) Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect Med 11:426–438
Sutter RW, Tangermann RH, Aylward RB et al (2001) Poliomyelitis eradication: progress, challenges for the end game, and preparation for the post-eradication era. Infect Dis Clin North Am 15:41–64
Vashishtha VM (2009) Polio eradication in India: need for caution. Indian J Pediatr 76:757
Wood DJ, Sutter RW, Dowdle WR (2000) Stopping poliovirus vaccination after eradication: issues and challenges. Bull World Health Organ 78:347–357
Wood N, Thorley B (2003) Viewpoint towards global poliomyelitis eradication: the successes and challenges for a developed country. J Paediatr Child Health 39:647–650
World Health Organization and UNICEF (2010) Progress on sanitation and drinking water: 2010 Update
World Health Organization (2000) Outbreak news. Wkly Epidemiol Rec 75:397–399
World Health Organization (2002) Manual for the virological investigation of poliomyelitis. World Health Organization (WHO/EPI/GEN/02.1), Geneva
World Health Organization (2003a) OPV virus circulation and evolution investigated in New Zealand. Polio Lab Netw Quaterly Update 9:2–3
World Health Organization (2003b) Progress towards the global eradication of poliomyletis, 2002. Wkly Epidemiol Rec 78:138–144
World Health Organization (2004) Manual for the virological investigation of poliomyletis. World Health Organization (WHO/EPI/GEN/04), Geneva
Yang CF, Naguib T, Yang SJ et al (2003) Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983–1993. J Virol 77:8366–8377
Yoshida H, Horie H, Matsuura K, Kitamura T, Hashizumi S, Miyamura T (2002) Prevalence of vaccine-derived polioviruses in the environment. J Gen Virol 83:1107–1111
Zaoutis T, Klein JD (1998) Enterovirus infections. Pediatr Rev 19:183–191
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer India
About this chapter
Cite this chapter
Dhole, T.N., Chatterjee, A. (2014). Water, Environmental Surveillance and Molecular Epidemiology of Poliovirus in India. In: Singh, P., Sharma, V. (eds) Water and Health. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1029-0_2
Download citation
DOI: https://doi.org/10.1007/978-81-322-1029-0_2
Published:
Publisher Name: Springer, New Delhi
Print ISBN: 978-81-322-1028-3
Online ISBN: 978-81-322-1029-0
eBook Packages: Earth and Environmental ScienceEarth and Environmental Science (R0)